Biotech Startups

GENEX, Inc. operates a data platform for genomic and healthcare information, letting individuals obtain and manage their whole-genome data for personal health management, medical access, and medical research. The company also offers whole-genome acquisition/management collaborative research and agency support services to clients.

1 investor

CellGen Tech develops cell-based medicines for rare and intractable diseases by engineering human adipose cells to produce therapeutic proteins. The company focuses on treating conditions caused by missing or deficient enzymes and proteins, with partnerships involving university medical experts.

1 investor

Cellspect develops next-generation clinical diagnostic reagents and in-vitro diagnostic products based on deep-tech, covering diagnostic technologies from biomarker discovery to treatment monitoring. It offers open-innovation partnerships with pharmaceutical companies and medical institutions, including point-of-testing and precision oncology products, based in Iwate, Japan.

1 investor

A Japanese biotech venture focused on drug discovery, developing novel pharmaceuticals with the goal of bringing innovative new drugs from Japan to the global market. It works from a proprietary compound library centered on protein kinase inhibitors built up through the founder's research activities.

1 investor

T Cell Nouveau develops Hybrid CAR-T cell therapies designed to treat solid tumors by enhancing immune system activation in suppressive tumor microenvironments. The clinical-stage biopharmaceutical company targets cancer patients and originated from research conducted at Mie University's Personalized Cancer Immunotherapy department.

1 investor

Nagasuna Mayu develops and manufactures silk protein products (sericin and fibroin) for application in cosmetics, healthcare, and materials, along with textile refining machinery. The company operates multiple facilities in Kyoto Prefecture, Japan, focusing on innovation in silk-based biotechnology.

1 investor

Nxera develops medicines by investing in science and technology, with a focus on structure-based drug design to create new treatments for patients. It operates in the biotech and pharmaceutical drug discovery space.

1 investor

A Japanese biotech company developing regenerative medicine technology (iBTA / in-Body Tissue Architecture) that grows the patient's own tissue to form implantable structures such as Biotube and Biosheet. Its applications include treatments for conditions like severe diabetic foot ulcers and gangrene.

1 investor

Human Life Code develops and commercializes novel therapeutics in specialty care areas such as cancer, autoimmune diseases, and retinal diseases. The company specializes in research, development, market launch, and lifecycle management of pharmaceutical products and regenerative medicine products.

1 investor

PharmaBio is Japan's first contract development and manufacturing organization (CDMO) for regenerative medicine and cell-based therapeutics. The company provides regulatory development support and manufacturing services for cell and tissue-derived pharmaceuticals.

1 investor

A biotech company specializing in high-density mass cultivation of stem cells, developing safe and compact culture devices and therapeutic cultivation technologies for clinical use based on non-woven scaffold technology.

1 investor

Kamui Pharma develops therapeutic compounds derived from probiotics for treating inflammatory bowel disease and other diseases. The company conducts drug discovery research and clinical trials focused on novel bioactive molecules.

1 investor

PorMedTec develops transplantable organs and tissues using genetically modified pigs for manufacturing and commercializing as regenerative medicine products. The company targets patients and healthcare systems facing severe organ shortages by providing alternatives to dialysis and other symptom-based treatments.

1 investor

MiRNDa, Inc. is a Japanese biotech company developing in-vitro diagnostic (IVD) medical devices based on RNA modification technology to detect an early "stage 0" of cancer.

1 investor

A company developing radioactive pharmaceuticals for cancer treatment with enhanced visibility. The company focuses on accelerating the delivery of innovative diagnostic and therapeutic agents to patients and healthcare providers.

1 investor

EditGene is an educational resource that explains modern genome and gene editing technologies, including CRISPR-based systems, base editing, prime editing, RNA editing, and AI-guided genome engineering. It is aimed at students, educators, and life science enthusiasts.

1 investor

Shanghai/Nanjing Sansheng Biotechnology develops, manufactures, and sells cell preservation products and related services, supporting cell therapy for medical and research institutions. Its offerings include cell cryopreservation agents used as pharmaceutical excipients, serving over 200 healthcare and research organizations in China.

1 investor

Shanghai Cell Therapy Group develops cell-therapy technologies and products aimed at curative treatment of tumors and aging-related diseases, including CAR-T therapies such as a non-lymphodepleting three-target CAR-T and a PD1 nanobody mesothelin-targeting CAR-T. The company also works on cell rejuvenation approaches to prevent and intervene in aging-related conditions, with operations in China.

1 investor

Guangdong HEC Pharmaceutical, founded in 2003, is a comprehensive pharmaceutical company engaged in the R&D, manufacturing, and commercialization of drugs, with a focus on innovative drugs as well as improved new drugs, generics, and biosimilars. The company concentrates on therapeutic areas including infectious diseases, chronic diseases, and oncology.

1 investor

TaiMed Biologics is a Taiwan-based biopharmaceutical company that develops monoclonal antibody therapies for HIV, including the long-acting TMB-365/TMB-380 combination and the CD4-targeted ADC platform extending into autoimmune diseases. It also operates a cGMP protein manufacturing facility and provides CDMO services such as process development, analytical method development, formulation development, and commercial manufacturing for antibody products.

1 investor

Deosen (Zhongxuan Biochemical) is a Chinese biotechnology manufacturer that develops, produces, and distributes biological hydrocolloids such as xanthan gum, welan gum, DSTA gum, gellan gum, and functional sugars derived from natural ingredients. Its products serve the food, oil, daily chemical, pharmaceutical, building materials, fertilizer, and health industries, with sales across more than 70 countries.

1 investor

Carrier Biomed works on extracellular vesicles (exosomes), lipid-bilayer particles 30-150 nm in size carrying cell-specific nucleic acids, proteins, and other molecules. The company explores their use in disease diagnosis and treatment, regenerative medicine, and as drug-delivery vehicles for targeted therapy.

1 investor

Guangdong Raynovent Biotech is a biotech company focused on discovering, developing, and commercializing innovative drugs for respiratory and metabolic diseases. Founded in October 2018 and headquartered in Guangzhou, China, its pipeline includes treatments for viral infections, type 2 diabetes, obesity, and MASH.

1 investor

Beijing-based Challenbio (北京层浪生物科技有限公司), founded in 2020, develops, manufactures, and sells IVD diagnostic instruments and reagents along with biomedical research instruments, with a focus on flow cytometry systems and automation. Its products serve both clinical diagnostics and scientific research markets in China.

1 investor